Participating institutional investors included Aisling Capital, Fidelity Biosciences, Kearny Venture Partners, OrbiMed Advisors, and Siemens Venture Capital. ViewRay said the investment was aimed at accelerating development of its MRI-guided radiation therapy system.
ViewRay's treatment planning and delivery software received U.S. Food and Drug Administration (FDA) 510(k) clearance in 2011, and its integrated imaging and radiotherapy delivery system is now pending 510(k) review, according to the company. The first ViewRay research system is undergoing final installation at the Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis.If you like this content, please share it with a colleague!
Copyright © 2012 AuntMinnie.com